simvastatin has been researched along with Dyslipidemia in 210 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 53 (25.24) | 29.6817 |
| 2010's | 143 (68.10) | 24.3611 |
| 2020's | 14 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Agrawal, A; Berger, JP; Cai, TQ; Desai, RC; Heck, JV; MacNaul, KL; Meinke, PT; Metzger, E; Moller, DE; Sahoo, SP; Santini, C; Wright, SD | 1 |
| Akiyama, TE; Berger, JP; Chang, CH; Doebber, TW; Einstein, M; Liu, K; Liu, W; McCann, ME; Meinke, PT; Wood, HB | 1 |
| Sashidhara, KV; Singh, SP | 1 |
| Alves Barros, AS; Barbosa, R; Cesar Matias Pereira, A; de Oliveira Carvalho, H; Faria E Souza, BS; Fernandes, CP; Leticia Elizandra Boettger, M; Lobato Duarte, J; Maciel Ferreira, A; Maciel Ferreira, I; Santos Rodrigues, AP; Tavares Carvalho, JC | 1 |
| Alkaabi, M; Amoodi, AA; Baraka, MA; Don, J; Elnour, AA; Farah, FH; Mazrouei, NA; Ramadan, A; Sadeq, A; Sam, KG | 1 |
| Ho, LT; Hwu, CM; Lee, IT; Sheu, WH; Wu, TH | 1 |
| Jiang, S; Li, Y; Liu, Y; Lu, C; Venners, SA | 1 |
| Chilbert, MR; Clark, CM; Ma, Q; Salah, S; VanDuyn, D | 1 |
| da Rocha, IG; da Silva Júnior, JG; da Silva Neto, JC; de Araújo, HDA; de Menezes Lima, VL; de Oliveira Assis, SP; Oliveira, RN | 1 |
| Allam, SH; Elgharbawy, NM; Mabrouk, MM; Salaam, SFA; Shaker, ESE | 1 |
| Andrejić-Višnjić, B; Arsenović, P; Čapo, I; Duborija-Kovačević, N; Horvat, O; Krga, M; Martić, N; Mijović, R; Pavlović, N; Prodanović, D; Rašković, A; Vujčić, M; Zaklan, D | 1 |
| Ahn, YM; Jung, J; Lee, SM; Park, SH; Shin, S | 1 |
| Bang, CN; Boman, K; Egstrup, K; Greve, AM; Kesäniemi, YA; Pedersen, TR; Ray, S; Wachtell, K | 1 |
| Al-Gareeb, AI; Al-Kuraishy, HM; Al-Naimi, MS; Hussien, NR; Rasheed, HA | 1 |
| Bell, KJL; Hayen, A; Zhu, L | 1 |
| Deng, C; Feng, X; Hu, CH; Liu, L; Liu, X; Zeng, Y | 1 |
| Caproni, KP; Dos Santos, L; Garcia, JAD; Martins, ÂM; Miranda, LPA; Silva Sarto, DAQ; Silva, J; Souza Carvalho, MDG; Souza, PS; Ureña, MJE; Vilas Boas, BM | 1 |
| da Costa Oliveira, M; Ongaratti, BR; Pereira-Lima, JFS; Rech, CGSL; Rissetti, G; Zeni, D | 1 |
| Bea, AM; Benaiges, D; Blanco-Vaca, F; Brea-Hernando, Á; Climent, E; Pedro-Botet, J; Perea, V; Pintó, X; Plana, N; Suárez-Tembra, M | 1 |
| Barros, AS; Carvalho, HO; Carvalho, JCT; da Cunha, EL; E Souza, BSF; Ferreira, IM; Taglialegna, T | 1 |
| Ji, K; Li, J; Liao, L; Qian, L; Tang, J; Tao, L; Wang, G; Wu, S; Xue, Y | 1 |
| Barter, PJ; Karlson, BW; Lundman, P; Nicholls, SJ; Palmer, MK | 1 |
| Bernik, MMS; Cerda, A; Dorea, EL; Fajardo, CM; Guimarães, ES; Gusukuma, MC; Hirata, MH; Hirata, RDC; Pinto, GA | 1 |
| Al Awadhi, M; Al Mahmeed, W; Al Tamimi, O; Al-Hinai, AT; Al-Mahruqi, F; Al-Rasadi, K; Al-Zakwani, I; Arafah, M; Santos, RD; Shehab, A | 1 |
| Aimaretti, G; Busti, A; Caputo, M; Castello, L; Chasseur, L; Karamouzis, I; Marzullo, P; Mele, C; Pagano, L; Ponziani, MC; Prodam, F; Samà, MT; Zavattaro, M | 1 |
| Auti, P; Gabhe, S; Mahadik, K | 1 |
| Han, SN; Tao, HL; Yang, WH; Yin, JJ; Zhang, LR | 1 |
| Deng, C; Hu, CH; Liu, XM; Zeng, YP; Zhao, XM | 1 |
| Barreto, J; Breder, I; Carvalho, LSF; Coelho Filho, OR; Coelho, OR; Cunha, J; Martins, NS; Matos-Souza, JR; Mello, DSS; Munhoz, DB; Nadruz, W; Silva, JCQE; Soares, AAS; Sposito, AC | 1 |
| Bugnon, S; Godinho, R; Gracin, T; Tataw, J | 1 |
| Abdul Rahman, H; Ahmad, Z; C Thambiah, S; Chew, BH; Hasan, S; Meor Anuar Shuhaili, MFR; Samsudin, IN; Stanslas, J | 1 |
| Bae, J; Kryzhanovski, VA; LeNarz, LA; Sponseller, CA; Zhao, Z; Zhu, Y | 1 |
| Bestehorn, K; Gitt, AK; Jannowitz, C; Karmann, B; Pittrow, D; Schaefer, JR; Sonntag, F; Weizel, A | 2 |
| Al-Dughaishi, T; Al-Hashmi, K; Al-Hinai, AT; Al-Rasadi, K; Al-Sabti, H; Al-Waili, K; Al-Zakwani, I; Baneerje, Y; Farhan, H; Habsi, KA | 1 |
| Camacho, X; Carter, AA; Gomes, T; Juurlink, DN; Mamdani, MM; Shah, BR | 1 |
| Kang, HJ; Kim, HS; Lee, JH; Oh, BH; Park, YB; Sohn, DW | 1 |
| Choi, BS; Chung, BH; Hong, YA; Jo, K; Kim, HD; Lee, J; Park, CW; Park, YK; Sun, IO; Yang, CW | 1 |
| Anderson, MS; Engel, SS; Hanson, ME; Musliner, T; Steinberg, H | 1 |
| Ahmad Alobaidi, AH | 1 |
| Reiner, Ž; Tedeschi-Reiner, E | 1 |
| Almeida, S; Bruxel, EM; Ferreira, ME; Fiegenbaum, M; Hutz, MH; Lima, LO; Pires, RC; Van der Sand, CR; Van der Sand, LC | 1 |
| Aras, R; Atta, AM; Atta, ML; Couto, RD; Pereira, MM; Santos, TP | 1 |
| Foody, JM; Hu, H; Neff, D; Ramey, DR; Sajjan, S; Tershakovec, AM; Tomassini, JE; Toth, PP; Tunceli, K | 1 |
| Ikemori, A; Kimura, K | 1 |
| Byington, RP; Crouse, JR; Elam, MB; Force, RW; Ginsberg, HN; Ismail-Beigi, F; Leiter, LA; Linz, PE; Lovato, LC; O'Connor, PJ; Papademetriou, V; Simmons, DL; Weiss, D | 1 |
| Borthwick, F; Jacome-Sosa, M; Mangat, R; Proctor, SD; Vine, DF; Warnakula, S | 1 |
| Al-Dosari, MS | 1 |
| Al-Hamaq, AO; Barakat, L; Bener, A; Dogan, M | 1 |
| Buse, JB; Cohen, RM; Cushman, WC; Cutler, JA; Evans, GW; Gerstein, HC; Goff, DC; Grimm, RH; Lipkin, EW; Margolis, KL; Morgan, TM; Narayan, KM; O'Connor, PJ; Riddle, MC; Sood, A | 1 |
| Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A | 1 |
| Castiglioni, L; Cosentino, M; Grandi, AM; Guasti, L; Klersy, C; Maio, RC; Maresca, AM; Marino, F; Mongiardi, C; Robustelli Test, L; Schembri, L | 1 |
| Fialkow, J; Legg, JC; Nedergaard, BS; Nelson, P; Neutel, JM; Ramstad, D; Robinson, JG; Rogers, WJ; Scott, R; Somaratne, R; Wasserman, SM; Weiss, R | 1 |
| Chen, E; Farnier, M; Johnson-Levonas, AO; McCrary Sisk, C; Mitchel, YB | 1 |
| Also, MA; Bastida, C; Letang, E; Miró, JM; Pericas, JM; Tuset, M | 1 |
| Chung, W; Han, KH; Hwang, YH; Jo, SK; Kim, HJ; Kim, SG; Lee, CH; Oh, KH; Song, YR; Yi, YJ | 1 |
| Fang, DZ; Gong, RR; Hu, MS; Jiang, Z; Lin, J; Liu, XJ; Qiu, L; Su, M; Wang, Q | 1 |
| Budoff, M; Folse, HJ; Goswami, D; Kahn, R; Rengarajan, B | 1 |
| Apanasovich, N; Dosta, N; Locatelli, F; März, W; Varushchanka, A; Wanner, C; Yakubtsevich, R | 1 |
| Ghushchyan, V; Nair, K; Saseen, JJ; Tuchscherer, RM | 1 |
| Ahmed, OA; Fahmy, UA; Hosny, KM; Zidan, AS | 1 |
| Ferreira, AM; Marques da Silva, P; Massano Cardoso, S | 1 |
| Amigó, N; Ascaso, JF; Blanco-Vaca, F; Cabré, A; Correig, X; Girona, J; Heras, M; Julve, J; Martínez-Hervás, S; Masana, L; Palomer, X; Plana, N; Quesada, H; Real, JT; Vázquez-Carrera, M | 1 |
| Schetz, D; Sein Anand, J | 1 |
| Farnier, M | 1 |
| Fazio, S | 1 |
| Choudhry, NK; Gagne, JJ; Kesselheim, AS; Landon, J; Wang, B | 1 |
| Adámková, V; Češka, R; Dlouhá, D; Hrubá, P; Hubáček, JA; Viklický, O; Vrablík, M; Zlatohlavek, L | 1 |
| Cífková, R; Krajčoviechová, A | 1 |
| Alexanderson, K; Halava, H; Kivimäki, M; Kjeldgård, L; Korhonen, MJ; Pentti, J; Vahtera, J; Westerlund, H | 1 |
| Elisaf, MS; Filippatos, TD | 2 |
| Gdula-Dymek, A; Krysiak, R; Marek, B; Okopień, B | 2 |
| Dinkler, J; Watson, K; Ziaeian, B | 1 |
| Aubonnet, P; Belenky, D; Berli, M; Calvo Vargas, CG; Foucher, C; Koch, HF; Lochocka, A; Reichert, P; Schaeffer, A | 1 |
| Hu, Y; Liu, K; Miao, C; Ren, L; Sun, B; Yan, M; Zhang, Y | 1 |
| Ding, Y; Guo, H; Guo, S; He, J; Li, S; Liu, J; Ma, J; Ma, R; Mu, L; Niu, Q; Yan, Y; Zhang, J; Zhang, M | 1 |
| Gouya, G; Herkner, H; Mesgarpour, B; Reichardt, B; Wolzt, M | 1 |
| Lopez, JL; Tayek, JA | 1 |
| Banach, M; Mikhailidis, DP; Serban, MC | 1 |
| Chen, YI; Kim, K; Medina, MW; Nickerson, DA; Rotter, JI; Smith, JD; Stevens, K; Theusch, E | 1 |
| Aziz, Z; Ong, YC | 1 |
| Cubitt, C; Dosé, AC; Medina, MW; Mitchel, K; Naidoo, D; Stevens, K; Theusch, E | 1 |
| Domingo, P; García Sarasola, A; Lamarca, K; Vidal, F | 1 |
| Goh, CC; Goh, SC; Koh, KH; Koh, YL; Tan, NC | 1 |
| Barrera-Durán, C; González-Ortiz, M; Hernández-Salazar, E; Martínez-Abundis, E | 1 |
| Bortoletto, MS; Petris, AJ; Souza, RK | 1 |
| Bangalore, S; DeMicco, DA; Fayyad, R; Kastelein, JJ; Laskey, R; Messerli, FH; Waters, DD | 1 |
| Agarwal, I; Ferket, BS; Fleischmann, KE; Hunink, MG; Khanji, M; Petersen, SE | 1 |
| Han, W; Li, J; Sun, L; Tang, H | 1 |
| Brunetti, ND; Correale, M; De Gennaro, L; Di Biase, M; Gaglione, A; Guastafierro, F; Santoro, F; Tarantino, N | 1 |
| Didona, B; Didona, D; Fania, L; Mazzanti, C; Tonanzi, T | 1 |
| Bain, AM; Bedimo, R; Busti, AJ; Eaton, SA; Nguyen, ST; Payne, KD; Rahman, AP | 1 |
| Mandell, BF | 1 |
| Dicklin, MR; Lubin, BC; Maki, KC; McKenney, JM; Reeves, MS | 1 |
| Bays, HE; Buttler, SM; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Arima, S; Kai, T; Kanamasa, K; Nakabou, M; Taniyama, Y | 1 |
| Kashyap, ML; Vo, AN | 1 |
| Buttler, SM; Kelly, MT; Mohiuddin, SM; Pepine, CJ; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Arora, A; Khan, BV; Pandian, A; Sperling, LS | 1 |
| Robinson, JG | 1 |
| Bowsman, M; Chen, M; Cordover, D; Fordstrom, P; Hale, C; Helmering, J; Kaufman, SA; Lloyd, DJ; Véniant, MM; Wang, M; Zhou, M | 1 |
| Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Salvadeo, SA | 1 |
| Hausenloy, DJ; Yellon, DM | 1 |
| Antic, T; Avitabile, T; Galvano, F; Li Volti, G; Malaguarnera, M; Vacante, M | 1 |
| Gao, Q; Jia, ZH; Li, LS; Liu, ZH; Qin, WS; Zeng, CH; Zheng, JM | 1 |
| Choi, BS; Hwang, HS; Hyoung, BJ; Jeon, YJ; Kim, YS; Lee, SY; Song, JC; Yang, CW; Yoon, HE | 1 |
| Antonopoulou, S; Demopoulos, CA; Iatrou, C; Iliopoulos, DG; Karantonis, HC; Perrea, DN; Theocharis, SE; Tsantila, N | 1 |
| Arneson, V; Budinski, D; Hounslow, N; Ose, L | 1 |
| Backes, JM; Howard, PA; Moriarty, PM; Ruisinger, JF | 1 |
| Kelly, MT; Kipnes, MS; Lele, A; Rhyne, JM; Roth, EM; Setze, CM; Sleep, DJ; Stolzenbach, JC | 1 |
| Charland, SL; Malone, DC | 1 |
| Cusi, K; Davidson, MH; Jones, PH; Kelly, MT; Setze, CM; Sleep, DJ; Stolzenbach, JC; Thakker, K | 1 |
| Cheung, BM; Tse, HF; Yiu, KH | 1 |
| Artamoshina, NE; Baĭder, LM; Belaia, OL; Kuropteva, ZV; Radzevich, AE | 1 |
| Briseño, GG; Mino-León, D | 1 |
| Cui, J; Guo, X; Krauss, RM; Mangravite, LM; Medina, MW; Nickerson, DA; Pressman, S; Rieder, MJ; Rotter, JI; Smith, JD | 1 |
| Fisman, EZ; Tenenbaum, A | 1 |
| Bays, HE; Kelly, MT; McKenney, JM; Obermeyer, K; Roth, EM; Setze, CM; Sleep, DJ; Thakker, KM | 1 |
| Ambrosius, WT; Chew, EY; Cushman, WC; Danis, RP; Davis, MD; Elam, MB; Esser, BA; Fine, LJ; Gangaputra, S; Genuth, S; Gerstein, HC; Ginsberg, HN; Goff, DC; Greven, CM; Hubbard, L; Lovato, JF; Perdue, LH; Schubart, U | 1 |
| Biancini, GB; Biasi, L; Cipriani, F; Dal Vesco, AM; Deon, M; Manfredini, V; Peralba, Mdo C; Treméa, R; Vanzin, CS; Vargas, CR; Wajner, M | 1 |
| Bangit, JR; Batsell, RR; Miraskar, RA; Reddy, KJ; Singh, M; Zaheer, MS | 1 |
| Pérez, A | 1 |
| Alexanderson, E; Alexanderson, G; Calleja, R; García-Rojas, L; Jácome, R; Jiménez, M; Martínez, A; Meave, A; Ochoa, JM | 1 |
| Akhlaghi, S; Amini, M; Azarpazhooh, MR; Bidmeshgi, S; Daloee, MH; Ferns, GA; Ghayour-Mobarhan, M; Momenzadeh, A; Moohebati, M; Parizadeh, SM; Paydar, R; Rahsepar, AA; Sahebkar, A; Tavallaie, S | 1 |
| Kang, HJ; Kim, HS; Kim, MK; Kim, SH; Kim, YJ; Lee, HY | 1 |
| Casulari, LA; Dos Santos, AM; Salgado, BJ; Salgado, JV | 1 |
| Krysiak, R; Okopien, B | 2 |
| Anyfantakis, ZA; Cokkinos, DV; Degiannis, D; Iakovis, P; Kroupis, C; Limas, C | 1 |
| Wilke, RA | 1 |
| Lyseng-Williamson, KA | 1 |
| Insull, W; Jiang, P; Krause, S; Padley, RJ; Parreno, RA; Superko, HR; Thakkar, RB; Toth, PP | 1 |
| Betteridge, J | 1 |
| Amini, M; Azarpazhooh, MR; Ferns, GA; Ghayour-Mobarhan, M; Mohammadi, M; Moohebati, M; Nematy, M; Parizadeh, SM; Rahsepar, AA; Sahebkar, A; Tavallaie, S | 1 |
| Nagashima, A; Ohashi, Y; Ooga, T; Sasaki, K; Sato, H; Soga, T; Tomita, M | 1 |
| Bullano, MF; Chang, CL; Cziraky, MJ; Gandhi, SK; Kamat, SA | 1 |
| Chen, Y; Chen, Z; Flattery, AM; Geoghagen, N; Hubbard, BK; Lassman, ME; McLaughlin, T; Pan, Y; Roddy, TP; Stefanni, AC; Strack, AM; Urosevic-Price, O; Wang, L; Wong, KK; Wu, W | 1 |
| Beals, C; Chen, F; Herman, GA; Hubbard, BK; Maridakis, V; O'Neill, EA; Strack, A; Wong, P | 1 |
| Cardoso, SM; da Silva, PM | 1 |
| Davies, GM; Krobot, KJ; Michailov, GV | 1 |
| Gorniakova, NB; Susekov, AV; Zubareva, MIu | 1 |
| Ginsberg, HN | 1 |
| Brinton, EA; Jiang, P; Kashyap, ML; Padley, RJ; Thakkar, RB; Vo, AN | 1 |
| Colman, E; Egan, A | 1 |
| Al-Khateeb, A; Ibrahim, S; Imran, K; Mohamed, MS; Yusof, Z; Zilfalill, BA | 1 |
| Catapano, AL; Norata, GD; Pirillo, A | 1 |
| Bhatnagar, A; Conklin, DJ; Haberzettl, P; Juvan, P; Prough, RA; Rezen, T; Rozman, D; Srivastava, S | 1 |
| Budinski, D; Eriksson, M; Hounslow, N | 2 |
| He, WK; He, ZC; Lai, Q; Liang, LY; Lu, DF; Luo, JD; Pan, XD; Wang, W; Wen, YH; Xiao, AY; Zeng, ZH | 1 |
| Oroma Owira, PM; Xulu, S | 1 |
| Akiyama, TE; Andrews, G; Bekkari, K; Carballo-Jane, E; Chen, F; Chen, J; Cumiskey, AM; Donnelly, MJ; Eiermann, GJ; Gagen, K; Gai, CL; Geoghagen, NS; Gorski, JN; Hansen, BC; Hubbard, BK; Koblan, KS; Kulick, AA; McLaren, DG; McNamara, LA; Mendoza, VH; Mitnaul, LJ; Petrov, A; Ping, X; Puig, O; Raubertas, R; Roddy, TP; Rosa, R; Strack, AM; Thankappan, A; Tong, X; Trinh, T; Voronin, GO; Wickham, LA; Wilsie, LC; Wolff, M; Wong, PH; Xue, J; Yin, W | 1 |
| Brudi, P; Dong, Q; Farnier, M; Johnson-Levonas, AO; Shah, A | 1 |
| Brewer, HB; Hu, B; Kastelein, JJ; Krueger, KA; McErlean, E; Nicholls, SJ; Nissen, SE; Shao, M; Wang, MD | 1 |
| Borch-Johnsen, K; Christensen, B; Graversen, L; Lauritzen, T; Sandbaek, A | 1 |
| Teramoto, T | 1 |
| Chapman, MJ | 1 |
| Jiang, P; Padley, RJ; Thakker, KM; Toth, PP | 1 |
| Semple, SJ | 1 |
| Ockene, IS | 1 |
| Armitage, J; Clarke, R; Collins, R; Hill, MR; Hopewell, JC; Offer, A; Otvos, JD; Parish, S | 1 |
| Alford, JC; Allen, RR; Nair, KV; Saseen, JJ | 1 |
| Filippatos, TD | 1 |
| Carru, C; Deiana, L; Loriga, G; Pisanu, E; Satta, AE; Sotgia, S; Zinellu, A | 1 |
| Isiguzoro, I; Okeahialam, BN | 1 |
| Ballantyne, CM; Belmont, JW; Brautbar, A; Keinan, A; Ma, L | 1 |
| Constantinides, A; de Vries, R; Dullaart, RP; Gautier, T; Lagrost, L; Tselepis, AD; van Leeuwen, JJ; van Pelt, LJ | 1 |
| Kuller, LH; Mackey, RH | 1 |
| Aghdaei, HR; Azarpazhooh, MR; Farrokhi, F; Ferns, GA; Ghaffarzadegan, K; Ghayour-Mobarhan, M; Moohebati, M; Norouzi, F; Sahebkar, A; Tavallaie, S | 1 |
| Adámkova, V; Ceska, R; Dlouha, D; Hubacek, JA; Lanska, V; Vrablik, M | 1 |
| Ceska, R; Marinov, I; Skrha, J; Stulc, T | 1 |
| Dubas, K; Kersnik, J; Kijowska, V; Seifert, B; Tomasik, T; Windak, A | 1 |
| Bots, ML; Grobbee, DE; Lafeber, M; Rodgers, A; Spiering, W; Thom, S; Visseren, FL; Webster, R | 1 |
| Davidson, MH; Toth, PP | 1 |
| Anderson, D; Bula, RL; Gulaya, V; Lankford, B; Lapu-Bula, R; Oduwole, A; Ofili, E; Pemu, PI | 1 |
| Schernthaner, G | 1 |
| Amir, K; Ashraf, R; Shaikh, AR | 1 |
| Bays, HE; McGovern, ME | 1 |
| Davidson, M | 1 |
| Balice, M; Chironi, G; Del-Pino, M; Gariepy, J; Levenson, J; Simon, A | 1 |
| Borges, JL | 1 |
| Battisti, WP; Dobs, A; Miller, M; Palmisano, J; Yuan, Z | 1 |
| Braun, SL; Guha-Ray, DK; Penn, R; Rains, KT; Sawyers, WG; Williams, RX | 1 |
| Deray, G; Isnard-Bagnis, C; Karie, S; Launay-Vacher, V | 1 |
| Ahmed, MH; Osman, MM; Saad, RA | 1 |
| Belaia, OL; Ivanova, LA; Kalmykova, VI; Kochergina, LG | 1 |
| Anderson, JL; Horne, BD; Jensen, JR; Lanman, RB; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Wolfert, RL; Yannicelli, HD | 1 |
| Jones, PH | 1 |
| Gonokhova, LG | 1 |
| Capell, WH; Eckel, RH; Gerard, LA; Hernandez, TL; Wolfe, P | 1 |
| Alsheikh-Ali, AA; Karas, RH | 1 |
| Chonchol, M; Cook, T; Kjekshus, J; Lindenfeld, J; Pedersen, TR | 1 |
| Demirtunc, R; Duman, D; Esertas, K; Sahin, S | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Koter-Michalak, M | 1 |
| Lachaine, J; Merikle, E; Montpetit, M; Rinfret, S; Tarride, JE | 1 |
| Doncheva, NI; Nikolov, KV; Vassileva, DP | 1 |
| Balbuena García, M; Castilla-Guerra, L; Fernández-Moreno, MC | 1 |
| Hostalek, U; Kassner, U; Steinhagen-Thiessen, E; Vogt, A | 1 |
| Anderson, JL; Horne, BD; Jensen, JR; Lavasani, F; May, HT; Muhlestein, JB; Pearson, RR; Yannicelli, HD | 1 |
| Thara, E; Towne, SP | 1 |
| Bays, H | 1 |
| Castiglioni, L; Cosentino, M; Ferrari, M; Gaudio, G; Grandi, AM; Guasti, L; Klersy, C; Lecchini, S; Maio, RC; Marino, F; Rasini, E; Venco, A | 1 |
| Bajorunas, DR; Davidson, MH; Karas, RH; Kashyap, ML; Keller, LH; Knopp, RH | 1 |
| Hansen, LB; Miller, AE; Saseen, JJ | 1 |
| Athyros, VG; Kakafika, AI; Karagiannis, A; Koragiannis, A; Mikhailidis, DP; Mikhalidis, DP | 1 |
| Branzi, A; Coccolo, F; Fallani, F; Grigioni, F; Magnani, G; Potena, L; Quarta, CC; Russo, A; Scalone, A | 1 |
43 review(s) available for simvastatin and Dyslipidemia
| Article | Year |
|---|---|
Lipid lowering agents of natural origin: An account of some promising chemotypes.
Topics: Animals; Biological Products; Dyslipidemias; Humans; Hypolipidemic Agents | 2017 |
A Systematic Review of Randomized Clinical Trials on the Efficacy and Safety of Pitavastatin.
Topics: Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Metabolic Syndrome; Pravastatin; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin | 2023 |
Combination Therapy of Ezetimibe and Rosuvastatin for Dyslipidemia: Current Insights.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2022 |
Statins an oft-prescribed drug is implicated in peripheral neuropathy: The time to know more.
Topics: Atorvastatin; Drug Interactions; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Peripheral Nervous System Diseases; Risk Factors; Simvastatin | 2019 |
Effects of age, gender and statin dose on lipid levels: Results from the VOYAGER meta-analysis database.
Topics: Age Factors; Aged; Atorvastatin; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Databases, Factual; Dose-Response Relationship, Drug; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Least-Squares Analysis; Lipids; Male; Middle Aged; Rosuvastatin Calcium; Sex Factors; Simvastatin; Treatment Outcome | 2017 |
Drug Treatment of Hyperlipidemia in Chinese Patients: Focus on the Use of Simvastatin and Ezetimibe Alone and in Combination.
Topics: Asian People; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Simvastatin | 2019 |
Management of dyslipidemia and hyperglycemia with a fixed-dose combination of sitagliptin and simvastatin.
Topics: Biomarkers; Blood Glucose; Dipeptidyl-Peptidase IV Inhibitors; Drug Combinations; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Lipids; Pyrazines; Simvastatin; Sitagliptin Phosphate; Treatment Outcome; Triazoles | 2013 |
[Clinical significance of treatment for dyslipidemia in CKD].
Topics: Azetidines; Cardiovascular Diseases; Cholesterol; Disease Progression; Drug Combinations; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Glomerulus; Kidney Tubules; Lipoproteins; Renal Insufficiency, Chronic; Risk Factors; Simvastatin | 2013 |
Efficacy and safety of pitavastatin versus simvastatin: a meta-analysis of randomized controlled trials.
Topics: Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Quinolines; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2014 |
Ezetimibe/statin combination therapy to treat patients with type 2 diabetes.
Topics: Azetidines; Biomarkers; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Simvastatin; Treatment Outcome | 2015 |
The role of PCSK9 in intestinal lipoprotein metabolism: synergism of statin and ezetimibe.
Topics: Animals; Azetidines; Cholesterol; Drug Combinations; Drug Synergism; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Absorption; Intestines; Lipoproteins; Proprotein Convertase 9; Proprotein Convertases; Receptors, LDL; Serine Endopeptidases; Simvastatin; Treatment Outcome | 2015 |
Dyslipidemia and cardiovascular disease in women.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Contraindications; Dyslipidemias; Estrogen Replacement Therapy; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Menopause; Patient Selection; Practice Guidelines as Topic; Risk Assessment; Risk Factors; Simvastatin; Triglycerides; United States | 2015 |
Safety considerations with fenofibrate/simvastatin combination.
Topics: Drug Combinations; Drug Interactions; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Risk Factors; Simvastatin | 2015 |
Implementation of the 2013 American College of Cardiology/American Heart Association Blood Cholesterol Guideline Including Data From the Improved Reduction of Outcomes: Vytorin Efficacy International Trial.
Topics: American Heart Association; Azetidines; Biomarkers; Cardiology; Cardiovascular Diseases; Cholesterol; Drug Combinations; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Practice Guidelines as Topic; Practice Patterns, Physicians'; Risk Assessment; Risk Factors; Simvastatin; Treatment Outcome; United States | 2015 |
Voriconazole-Induced Hepatitis via Simvastatin- and Lansoprazole-Mediated Drug Interactions: A Case Report and Review of the Literature.
Topics: Adult; Antifungal Agents; Biotransformation; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Dyslipidemias; Gastroesophageal Reflux; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Jaundice, Obstructive; Lansoprazole; Liver; Male; Polypharmacy; Proton Pump Inhibitors; Pulmonary Aspergillosis; Simvastatin; Voriconazole | 2016 |
Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Simvastatin | 2016 |
Systematic review of red yeast rice compared with simvastatin in dyslipidaemia.
Topics: Biological Products; Dyslipidemias; Humans; Hypolipidemic Agents; Lipids; Randomized Controlled Trials as Topic; Simvastatin | 2016 |
Drug therapies for HIV-related metabolic disorders.
Topics: Cardiovascular Diseases; Dyslipidemias; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium; Simvastatin | 2016 |
Fenofibrate/simvastatin fixed-dose combination in the treatment of mixed dyslipidemia: safety, efficacy, and place in therapy.
Topics: Animals; Biomarkers; Drug Combinations; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Simvastatin; Treatment Outcome; Triglycerides | 2017 |
Fixed-dose combination of extended-release niacin plus simvastatin for lipid disorders.
Topics: Animals; Cholesterol; Clinical Trials as Topic; Coronary Disease; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Humans; Hypolipidemic Agents; Niacin; Practice Guidelines as Topic; Risk Factors; Simvastatin; Triglycerides | 2008 |
Targeting multiple dyslipidemias with fixed combinations--focus on extended release niacin and simvastatin.
Topics: Cardiovascular Diseases; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Patient Compliance; Simvastatin; Treatment Outcome | 2008 |
Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.
Topics: Aged; Cardiovascular Diseases; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niacin; Simvastatin; Treatment Outcome | 2009 |
Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Disease Progression; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Risk Factors; Risk Reduction Behavior; Simvastatin; United Kingdom | 2009 |
Does simvastatin cause more myotoxicity compared with other statins?
Topics: Clinical Trials as Topic; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; Drug Interactions; Dyslipidemias; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Rhabdomyolysis; Risk Factors; Simvastatin | 2009 |
Prediction of cardiovascular event risk reduction from lipid changes associated with high potency dyslipidemia therapy.
Topics: Algorithms; Azetidines; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Female; Humans; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Niacin; Prognosis; Randomized Controlled Trials as Topic; Risk Reduction Behavior; Simvastatin | 2010 |
A new paradigm for managing dyslipidemia with combination therapy: laropiprant + niacin + simvastatin.
Topics: Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Niacin; Simvastatin | 2010 |
High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Databases, Nucleic Acid; Dose-Response Relationship, Drug; Dyslipidemias; Electronic Health Records; Genetic Association Studies; Genetic Markers; Heptanoic Acids; Humans; Obesity; Pravastatin; Pyrroles; Risk Assessment; Simvastatin; Treatment Outcome | 2011 |
Niacin extended release (ER)/simvastatin (Simcor®): a guide to its use in lipid regulation.
Topics: Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Humans; Hypolipidemic Agents; Lipids; Niacin; Simvastatin | 2010 |
Pitavastatin - results from phase III & IV.
Topics: Atorvastatin; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Pravastatin; Pyrroles; Quinolines; Simvastatin | 2010 |
[Evidence-based grounds of the efficacy of simvastatin (zocor): 15 years later].
Topics: Dyslipidemias; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin; Treatment Outcome | 2010 |
Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.
Topics: Adult; Cardiovascular Diseases; Diabetes Complications; Drug Combinations; Drug Monitoring; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lipoproteins; Risk Factors; Simvastatin | 2011 |
Pitavastatin: clinical effects from the LIVES Study.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides | 2011 |
Pitavastatin: novel effects on lipid parameters.
Topics: Apolipoprotein A-I; Apolipoproteins B; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Europe; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Lipids; Multicenter Studies as Topic; Plaque, Atherosclerotic; Pyrroles; Quinolines; Randomized Controlled Trials as Topic; Russia; Simvastatin; Triglycerides | 2011 |
A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.
Topics: Atorvastatin; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
[Lipid therapy in daily routine].
Topics: Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Female; General Practice; Germany; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Myocardial Infarction; Practice Patterns, Physicians'; Prospective Studies; Simvastatin | 2012 |
Simvastatin plus ezetimibe: combination therapy for the management of dyslipidaemia.
Topics: Azetidines; Cholesterol, HDL; Disease Management; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Humans; Lipoproteins, LDL; Simvastatin | 2005 |
Is dyslipidaemia important if we control glycaemia?
Topics: Cardiovascular Diseases; Cholesterol, HDL; Coronary Disease; Diabetes Mellitus; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Rhabdomyolysis; Risk Factors; Simvastatin | 2005 |
Considerations in the treatment of dyslipidemia associated with chronic kidney failure and renal transplantation.
Topics: Atorvastatin; Comorbidity; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Failure, Chronic; Kidney Transplantation; Lovastatin; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2005 |
[Statins in patients with kidney failure: efficacy, tolerance, and prescription guidelines in patients with chronic kidney disease and renal transplant].
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol; Cholesterol, LDL; Dyslipidemias; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Graft Rejection; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Failure, Chronic; Liver Transplantation; Middle Aged; Pravastatin; Primary Prevention; Prospective Studies; Proteinuria; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors | 2006 |
[Statins in the secondary prevention of ictus in the community].
Topics: Anticholesteremic Agents; Cholesterol; Cohort Studies; Dyslipidemias; Follow-Up Studies; Humans; Hypolipidemic Agents; Incidence; Ischemic Attack, Transient; Meta-Analysis as Topic; Middle Aged; Practice Guidelines as Topic; Prospective Studies; Randomized Controlled Trials as Topic; Risk; Simvastatin; Spain; Stroke; Time Factors | 2007 |
Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.
Topics: Atorvastatin; Azetidines; Cholesterol, HDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Niacin; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2007 |
Do statins reduce events in patients with metabolic syndrome?
Topics: C-Reactive Protein; Cholesterol, LDL; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Metabolic Syndrome; Niacin; Primary Prevention; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2008 |
Safety of niacin and simvastatin combination therapy.
Topics: Anticholesteremic Agents; Drug Therapy, Combination; Dyslipidemias; Humans; Hypolipidemic Agents; Niacin; Risk Factors; Simvastatin; Transaminases | 2008 |
67 trial(s) available for simvastatin and Dyslipidemia
| Article | Year |
|---|---|
Combined lipid goal attainment in patients with type 2 diabetes and dyslipidemia: A head-to-head comparative trial of statins.
Topics: Cholesterol; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Goals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium; Simvastatin; Treatment Outcome | 2022 |
Relation of Lipid-Lowering Therapy to Need for Aortic Valve Replacement in Patients With Asymptomatic Mild to Moderate Aortic Stenosis.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Aortic Valve; Aortic Valve Stenosis; Asymptomatic Diseases; Biomarkers; Disease Progression; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Echocardiography, Doppler; Ezetimibe; Female; Follow-Up Studies; Heart Valve Prosthesis Implantation; Humans; Lipoproteins, LDL; Male; Middle Aged; Prospective Studies; Severity of Illness Index; Simvastatin; Time Factors; Treatment Outcome | 2019 |
Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Cause of Death; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Lipids; Male; Middle Aged; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2020 |
Red yeast rice induces less muscle fatigue symptom than simvastatin in dyslipidemic patients: a single center randomized pilot trial.
Topics: Adult; Biological Products; Biomarkers; China; Dietary Supplements; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Muscle Fatigue; Muscle, Skeletal; Pilot Projects; Simvastatin; Time Factors; Treatment Outcome | 2017 |
Effects of ezetimibe/simvastatin 10/20 mg vs. atorvastatin 20 mg on apolipoprotein B/apolipoprotein A1 in Korean patients with type 2 diabetes mellitus: results of a randomized controlled trial.
Topics: Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Asian People; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Female; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Pyrroles; Republic of Korea; Simvastatin; Treatment Outcome | 2013 |
Effect of Nigella sativa and Allium sativum coadminstered with simvastatin in dyslipidemia patients: a prospective, randomized, double-blind trial.
Topics: Adult; Allyl Compounds; Cholesterol; Combined Modality Therapy; Dietary Supplements; Dyslipidemias; Female; Garlic; Humans; Lipid Metabolism; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Nigella sativa; Phytotherapy; Plant Preparations; Prospective Studies; Seeds; Simvastatin; Sulfides; Treatment Outcome; Triglycerides; Young Adult | 2014 |
Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial.
Topics: Adult; Aged; Blood Glucose; Cholesterol, HDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipid Metabolism; Male; Middle Aged; Risk Factors; Simvastatin; Thiazolidinediones; Treatment Outcome | 2014 |
Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial.
Topics: Adult; Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Disease Management; Dyslipidemias; Female; Fenofibrate; Glycated Hemoglobin; Humans; Hypolipidemic Agents; Male; Middle Aged; Myocardial Infarction; Outcome and Process Assessment, Health Care; Risk Factors; Risk Reduction Behavior; Simvastatin; Stroke | 2014 |
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid | 2014 |
Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Azetidines; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2014 |
Effects of extended-release niacin/laropiprant, simvastatin, and the combination on correlations between apolipoprotein B, LDL cholesterol, and non-HDL cholesterol in patients with dyslipidemia.
Topics: Adult; Aged; Apolipoproteins B; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Linear Models; Middle Aged; Niacin; Risk Factors; Simvastatin; Time Factors; Treatment Outcome | 2014 |
Comparison of the efficacy and safety profile of morning administration of controlled-release simvastatin versus evening administration of immediate-release simvastatin in chronic kidney disease patients with dyslipidemia.
Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Double-Blind Method; Drug Administration Schedule; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Renal Insufficiency, Chronic; Simvastatin; Treatment Outcome; Triglycerides | 2014 |
Dyslipidemia in chronic kidney disease: randomized controlled trial of colestilan versus simvastatin in dialysis patients.
Topics: Adult; Aged; Bile Acids and Salts; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Dyslipidemias; Europe; Female; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Simvastatin; Time Factors; Treatment Outcome; Triglycerides | 2014 |
Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
Topics: Adult; Aged; Antioxidants; Biomarkers; Cholesterol, HDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; High-Density Lipoproteins, Pre-beta; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Metabolomics; Middle Aged; Niacin; Oxidants; Particle Size; Prospective Studies; Simvastatin; Spain; Time Factors; Treatment Outcome; Up-Regulation | 2015 |
New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies.
Topics: Aged; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cystatin C; Double-Blind Method; Drug Combinations; Dyslipidemias; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Simvastatin; Time Factors; Treatment Outcome; Triglycerides | 2015 |
An Evaluation on the Effect of Health Education and of Low-Dose Statin in Dyslipidemia among Low-Income Rural Uyghur Adults in Far Western China: A Comprehensive Intervention Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; China; Drug Administration Schedule; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Minority Groups; Patient Education as Topic; Poverty; Prevalence; Rural Health; Simvastatin; Treatment Outcome; Young Adult | 2015 |
Statin-induced expression change of INSIG1 in lymphoblastoid cell lines correlates with plasma triglyceride statin response in a sex-specific manner.
Topics: Adult; Aged; Cell Line; Dyslipidemias; Female; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracellular Signaling Peptides and Proteins; Lymphocytes; Male; Membrane Proteins; Middle Aged; Pharmacogenetics; Pharmacogenomic Variants; Sex Factors; Simvastatin; Treatment Outcome; Triglycerides | 2017 |
Persistent Effects of Intensive Glycemic Control on Retinopathy in Type 2 Diabetes in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Follow-On Study.
Topics: Aged; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Humans; Hypolipidemic Agents; Male; Middle Aged; Risk Factors; Simvastatin | 2016 |
[Effect of simvastatin plus inulin in comparison with simvastatin plus ezetimibe on the treatment of mixed dyslipidemia].
Topics: Adult; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Inulin; Male; Middle Aged; Simvastatin; Treatment Outcome | 2016 |
Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, VLDL; Cross-Over Studies; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Omega-3; Female; Humans; Hypertriglyceridemia; Lipoproteins; Male; Middle Aged; Sex Factors; Simvastatin; Time Factors; Triglycerides | 2008 |
Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.
Topics: Analysis of Variance; Atorvastatin; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Prospective Studies; Pyrimidines; Pyrroles; Research Design; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome | 2008 |
Comparison of the effect of lipophilic and hydrophilic statins on serum adiponectin levels in patients with mild hypertension and dyslipidemia: Kinki Adiponectin Interventional (KAI) Study.
Topics: Adiponectin; Adipose Tissue; Adult; Aged; Aged, 80 and over; C-Reactive Protein; Cholesterol; Dyslipidemias; Female; Humans; Hydrophobic and Hydrophilic Interactions; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Male; Middle Aged; Pravastatin; Prospective Studies; Simvastatin | 2008 |
Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Young Adult | 2009 |
Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients.
Topics: Adult; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome | 2009 |
Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus.
Topics: Apoprotein(a); Blood Glucose; Body Mass Index; Carnitine; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoprotein(a); Male; Middle Aged; Simvastatin; Triglycerides | 2009 |
Comparison of pitavastatin with simvastatin in primary hypercholesterolaemia or combined dyslipidaemia.
Topics: Adult; Aged; Biomarkers; Double-Blind Method; Dyslipidemias; Female; Humans; Hypercholesterolemia; Hypolipidemic Agents; Male; Middle Aged; Quinolines; Simvastatin; Treatment Outcome | 2009 |
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, VLDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
Combined influence of LDLR and HMGCR sequence variation on lipid-lowering response to simvastatin.
Topics: 3' Untranslated Regions; Black or African American; California; Cell Line; Dyslipidemias; Haplotypes; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Lymphocytes; Polymorphism, Single Nucleotide; Receptors, LDL; Simvastatin; Treatment Outcome; White People | 2010 |
The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.
Topics: Dyslipidemias; Fenofibrate; Hypolipidemic Agents; Metabolic Syndrome; Simvastatin | 2010 |
Effects of medical therapies on retinopathy progression in type 2 diabetes.
Topics: Antihypertensive Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Retinopathy; Disease Progression; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Follow-Up Studies; Glycated Hemoglobin; Humans; Hyperglycemia; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Male; Middle Aged; Simvastatin | 2010 |
Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic type 2 diabetic patients.
Topics: Adult; Aged; Aryldialkylphosphatase; C-Reactive Protein; Comet Assay; Diabetes Mellitus, Type 2; DNA Damage; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leukocytes; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Simvastatin | 2010 |
Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: A randomized, double-blind, placebo-controlled, cross-over trial.
Topics: Chaperonin 60; Double-Blind Method; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2011 |
Prospective randomized comparison between omega-3 fatty acid supplements plus simvastatin versus simvastatin alone in Korean patients with mixed dyslipidemia: lipoprotein profiles and heart rate variability.
Topics: Adult; Aged; Asian People; Cholesterol; Dietary Supplements; Docosahexaenoic Acids; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Eicosapentaenoic Acid; Fatty Acids, Omega-3; Female; Heart Rate; Humans; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Prospective Studies; Republic of Korea; Simvastatin; Triglycerides | 2011 |
Effects of low-dose of niacin associated to simvastatin in the treatment of mixed dyslipidemia Salgad.
Topics: Aged; Aspirin; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Drug Combinations; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Metabolic Syndrome; Middle Aged; Niacin; Platelet Aggregation Inhibitors; Prospective Studies; Simvastatin; Vasodilator Agents | 2010 |
Increased inflammatory response in patients with dilated cardiomyopathy is associated with dyslipidemia: Effects of statin therapy.
Topics: Cardiomyopathy, Dilated; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Middle Aged; Prospective Studies; Simvastatin | 2011 |
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Pyrroles; Simvastatin; Treatment Outcome; United States | 2010 |
Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antioxidants; Cross-Over Studies; Double-Blind Method; Dyslipidemias; Female; Humans; Male; Middle Aged; Oxidative Stress; Placebos; Reactive Oxygen Species; Simvastatin; Young Adult | 2011 |
The effects of simvastatin treatment on plasma lipid-related biomarkers in men with dyslipidaemia.
Topics: Adult; Aged; Biomarkers; Cross-Over Studies; Double-Blind Method; Dyslipidemias; Fatty Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Simvastatin; Treatment Outcome | 2011 |
Lymphocyte-suppressing effect of simvastatin in mixed dyslipidemic patients but not impaired glucose tolerance patients.
Topics: Blood Glucose; C-Reactive Protein; Cytokines; Dyslipidemias; Female; Glucose Intolerance; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Simvastatin; T-Lymphocytes | 2011 |
The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses.
Topics: Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Male; Placebo Effect; Simvastatin | 2011 |
Long-term efficacy of pitavastatin versus simvastatin.
Topics: Aged; Cholesterol, LDL; Coronary Artery Disease; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Quinolines; Simvastatin | 2011 |
Comparative efficacy of pitavastatin and simvastatin in high-risk patients: a randomized controlled trial.
Topics: Aged; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Quinolines; Simvastatin | 2011 |
The effects of simvastatin on left ventricular hypertrophy and left ventricular function in patients with essential hypertension.
Topics: Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Benzoates; Blood Pressure; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Lipids; Male; Simvastatin; Telmisartan; Treatment Outcome; Ultrasonography; Ventricular Function, Left | 2011 |
Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.
Topics: Adult; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fenofibrate; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome | 2011 |
Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial.
Topics: Aged; Atorvastatin; Benzodiazepines; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2011 |
Niacin extended-release/simvastatin combination therapy produces larger favorable changes in high-density lipoprotein particles than atorvastatin monotherapy.
Topics: Atorvastatin; Biomarkers; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Magnetic Resonance Spectroscopy; Male; Middle Aged; Niacin; Particle Size; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome; United States | 2012 |
Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Arterial Occlusive Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Placebos; Predictive Value of Tests; Proportional Hazards Models; Risk Factors; Simvastatin | 2012 |
LDL S-homocysteinylation decrease in chronic kidney disease patients undergone lipid lowering therapy.
Topics: Allantoin; Apolipoproteins B; Azetidines; Cholesterol, LDL; Drug Combinations; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Female; Homocystine; Humans; Hypolipidemic Agents; Lipid Metabolism; Male; Malondialdehyde; Middle Aged; Oxidative Stress; Pilot Projects; Renal Insufficiency, Chronic; Simvastatin; Sulfhydryl Compounds; Uric Acid | 2012 |
Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.
Topics: Angiopoietin-Like Protein 3; Angiopoietin-like Proteins; Angiopoietins; Apolipoproteins; Apolipoproteins B; Atorvastatin; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Polymorphism, Single Nucleotide; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2012 |
Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Bezafibrate; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Male; Middle Aged; Simvastatin; Triglycerides | 2012 |
Effects of statin therapy on serum trace element status in dyslipidemic patients: results of a randomized placebo-controlled cross-over trial.
Topics: Adult; Aged; Aged, 80 and over; Ceruloplasmin; Cross-Over Studies; Double-Blind Method; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Simvastatin; Superoxide Dismutase; Trace Elements; Young Adult | 2012 |
The effect of simvastatin and fenofibrate on the expression of leukocyte adhesion molecules and lipopolysaccharide receptor CD14 in type 2 diabetes mellitus.
Topics: Adult; CD11a Antigen; CD18 Antigens; Cross-Over Studies; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Integrin alpha4; Leukocytes; Lipids; Lipopolysaccharide Receptors; Male; Middle Aged; Simvastatin | 2012 |
The evening versus morning polypill utilization study: the TEMPUS rationale and design.
Topics: Administration, Oral; Antihypertensive Agents; Aspirin; Biomarkers; Blood Platelets; Blood Pressure; Cardiovascular Diseases; Cholesterol, LDL; Clinical Protocols; Cross-Over Studies; Drug Chronotherapy; Drug Combinations; Dyslipidemias; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Lisinopril; Netherlands; Platelet Aggregation Inhibitors; Primary Prevention; Prospective Studies; Research Design; Simvastatin; Tablets; Time Factors; Treatment Outcome | 2014 |
Comparison between duration dependent effects of Simvastatin and Gemfibrozil on dyslipidemia in patients with type 2 diabetes.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Male; Risk Factors; Simvastatin; Time Factors; Triglycerides | 2005 |
The effect of simvastatin on triglyceride-rich lipoproteins in patients with type 2 diabetic dyslipidemia: a SILHOUETTE trial sub-study.
Topics: Aged; Cholesterol, VLDL; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Female; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome; Triglycerides | 2006 |
An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Atorvastatin; Cross-Over Studies; Delayed-Action Preparations; Drug Carriers; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pyrroles; Reference Values; Simvastatin; Treatment Outcome | 2006 |
[Experience in coenzyme Q10 application in complex therapy of coronary heart disease with dyslipidemia].
Topics: Ceruloplasmin; Coenzymes; Coronary Disease; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Lipid Peroxidation; Male; Middle Aged; Simvastatin; Transferrin; Ubiquinone | 2006 |
The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
Topics: Atherosclerosis; Biomarkers; C-Reactive Protein; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Inflammation; Male; Middle Aged; Phospholipases A; Phospholipases A2; Simvastatin | 2006 |
Time course of C-reactive protein reduction with simvastatin therapy in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Cross-Over Studies; Diabetes Mellitus, Type 2; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Simvastatin | 2006 |
Simvastatin for secondary prevention of all-cause mortality and major coronary events in patients with mild chronic renal insufficiency.
Topics: Adult; Aged; Anticholesteremic Agents; Coronary Disease; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Renal Insufficiency, Chronic; Risk Factors; Scandinavian and Nordic Countries; Simvastatin | 2007 |
Simvastatin improves endothelial function in patents with subclinical hypothyroidism.
Topics: Adult; Analysis of Variance; Cholesterol; Dyslipidemias; Endothelium, Vascular; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothyroidism; Prospective Studies; Simvastatin; Thyroxine; Triglycerides; Vasodilation | 2007 |
[The effect of statins on lipids peroxidation and activities of antioxidants enzymes in patients with dyslipidemia].
Topics: Adult; Aged; Antioxidants; Atorvastatin; Catalase; Dyslipidemias; Erythrocyte Membrane; Female; Glutathione Peroxidase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Middle Aged; Pravastatin; Pyrroles; Simvastatin; Superoxide Dismutase; Treatment Outcome | 2006 |
Lipid-modifying and pleiotropic effects of gemfibrozil, simvastatin and pravastatin in patients with dyslipidemia.
Topics: Dyslipidemias; Female; Gemfibrozil; Humans; Hypolipidemic Agents; Lipids; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 2006 |
Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Simvastatin; Triglycerides | 2008 |
Long-term safety and efficacy of a combination of niacin extended release and simvastatin in patients with dyslipidemia: the OCEANS study.
Topics: Adult; Aged; Aged, 80 and over; Cholesterol; Cholesterol, HDL; Delayed-Action Preparations; Drug Combinations; Dyslipidemias; Female; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Longitudinal Studies; Male; Middle Aged; Niacin; Simvastatin; Triglycerides | 2008 |
Switching statin therapy using a pharmacist-managed therapeutic conversion program versus usual care conversion among indigent patients.
Topics: Adult; Aged; Azetidines; Cholesterol, LDL; Colorado; Drug Combinations; Dyslipidemias; Ezetimibe, Simvastatin Drug Combination; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Pharmacists; Poverty; Pyrimidines; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2008 |
Safety and efficacy of ezetimibe with low doses of simvastatin in heart transplant recipients.
Topics: Aged; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Heart Transplantation; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome | 2008 |
100 other study(ies) available for simvastatin and Dyslipidemia
| Article | Year |
|---|---|
Design and synthesis of potent and subtype-selective PPARalpha agonists.
Topics: Animals; Cricetinae; Dogs; Drug Design; Dyslipidemias; Haplorhini; Hypolipidemic Agents; Molecular Structure; PPAR alpha; Rats; Structure-Activity Relationship; Transcriptional Activation | 2006 |
Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.
Topics: Animals; Blood Glucose; Butyric Acid; Cell Line; Cholesterol; Cricetinae; Diabetes Mellitus, Type 2; Dogs; Drug Discovery; Dyslipidemias; Female; Humans; Indoles; Male; Mice; PPAR gamma; Rats; Structure-Activity Relationship | 2009 |
The effects of Rosmarinus officinalis L. essential oil and its nanoemulsion on dyslipidemic Wistar rats.
Topics: Animals; Atherosclerosis; Cholesterol, LDL; Dyslipidemias; Hypercholesterolemia; Hypertriglyceridemia; Nanoparticle Drug Delivery System; Oils, Volatile; Rats; Rats, Wistar; Rosmarinus; Simvastatin; Triglycerides | 2020 |
Associations of Two Common Polymorphisms in
Topics: Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Genetic Predisposition to Disease; Genotype; Humans; Lipids; Methylenetetrahydrofolate Reductase (NADPH2); Polymorphism, Single Nucleotide; Simvastatin | 2022 |
Antihyperlipidemic Activity of Glycoconjugated Phthalimides in Mice Submitted to a Model of Dyslipidemia and Insulin Resistance.
Topics: Animals; Carboxymethylcellulose Sodium; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Hormones; Hypolipidemic Agents; Insulin Resistance; Insulins; Lipoproteins, VLDL; Mice; Obesity; Phthalimides; Simvastatin; Transaminases; Triglycerides; Uric Acid | 2022 |
Simvastatin and non-segmental vitiligo: A new potential treatment option?
Topics: Dyslipidemias; Humans; Lipoproteins, LDL; Simvastatin; Triglycerides; Vitiligo | 2022 |
Antihyperlipidemic potential of dietary supplementation with carnosine in high-fat diet-fed rats.
Topics: Animals; Carnosine; Diet, High-Fat; Dietary Supplements; Dyslipidemias; Hypolipidemic Agents; Liver; Male; Rats; Rats, Wistar; Simvastatin; Triglycerides | 2023 |
Reshaping the gut microbiome and bile acid composition by Gyejibongnyeong-hwan ameliorates western diet-induced dyslipidemia.
Topics: Animals; Bile Acids and Salts; Cholesterol; Diet, Western; Dyslipidemias; Gastrointestinal Microbiome; Liver; Mice; Mice, Inbred C57BL; Simvastatin | 2023 |
Brown adipose tissue activity is modulated in olanzapine-treated young rats by simvastatin.
Topics: Adipose Tissue, Brown; Animals; Antipsychotic Agents; Blood Glucose; Body Temperature; Cholesterol; Dyslipidemias; Eating; Female; Hypolipidemic Agents; Liver; Locomotion; Olanzapine; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Rats, Sprague-Dawley; Simvastatin; Triglycerides; Uncoupling Protein 1; Weight Gain | 2020 |
Grape juice attenuates left ventricular hypertrophy in dyslipidemic mice.
Topics: Animals; Blood Pressure; C-Reactive Protein; CD40 Ligand; Collagen; Diet, High-Fat; Dyslipidemias; Fruit and Vegetable Juices; Heart Ventricles; Hypertrophy, Left Ventricular; Male; Matrix Metalloproteinase 2; Mice; Mice, Inbred C57BL; Mice, Knockout; Protective Agents; Receptors, LDL; Simvastatin; Vitis | 2020 |
Lipid profile and response to statin therapy in patients with hypopituitarism.
Topics: Adult; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypopituitarism; Lipids; Simvastatin | 2021 |
LDL Cholesterol Reduction Variability with Different Types and Doses of Statins in Monotherapy or Combined with Ezetimibe. Results from the Spanish Arteriosclerosis Society Dyslipidaemia Registry.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Registries; Rosuvastatin Calcium; Simvastatin | 2022 |
Effect of the treatment with Euterpe oleracea Mart. oil in rats with Triton-induced dyslipidemia.
Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Dyslipidemias; Euterpe; Hypolipidemic Agents; Lipids; Lipoproteins; Lipoproteins, LDL; Male; Plant Oils; Rats; Rats, Wistar; Simvastatin; Triglycerides | 2017 |
Effects of short-term add-on ezetimibe to statin treatment on expression of adipokines and inflammatory markers in diabetic and dyslipidemic patients.
Topics: Adipokines; Adult; Aged; Anticholesteremic Agents; Biomarkers; Blood Glucose; Cytokines; Diabetes Mellitus; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Lipids; Male; Middle Aged; Monocytes; RNA, Messenger; Simvastatin | 2017 |
Sex disparity in the management and outcomes of dyslipidemia of diabetic patients in the Arabian Gulf: findings from the CEPHEUS study.
Topics: Adult; Aged; Atherosclerosis; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Male; Middle Aged; Middle East; Rosuvastatin Calcium; Sex Characteristics; Simvastatin | 2018 |
Baseline glucose homeostasis predicts the new onset of diabetes during statin therapy: A retrospective study in real life.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Atorvastatin; Blood Glucose; Diabetes Mellitus; Dyslipidemias; Female; Follow-Up Studies; Glucose Metabolism Disorders; Homeostasis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Retrospective Studies; Simvastatin; Young Adult | 2017 |
Bioanalytical method development and its application to pharmacokinetics studies on Simvastatin in the presence of piperine and two of its synthetic derivatives.
Topics: Administration, Oral; Alkaloids; Animals; Benzodioxoles; Biological Availability; Drug Compounding; Drug Synergism; Dyslipidemias; Feasibility Studies; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Piperidines; Polyunsaturated Alkamides; Rats; Rats, Wistar; Simvastatin | 2019 |
Simvastatin improves olanzapine-induced dyslipidemia in rats through inhibiting hepatic mTOR signaling pathway.
Topics: Animals; Down-Regulation; Dyslipidemias; Fatty Liver; Female; Hep G2 Cells; Humans; Lipogenesis; Liver; Olanzapine; Rats, Sprague-Dawley; Signal Transduction; Simvastatin; Sterol Regulatory Element Binding Protein 1; TOR Serine-Threonine Kinases | 2019 |
Prevalence, treatment, and control of dyslipidemia in diabetic participants of two brazilian cohorts: a place far from heaven.
Topics: Anticholesteremic Agents; Blood Pressure; Brazil; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Male; Middle Aged; Prevalence; Risk Factors; Simvastatin; Triglycerides | 2019 |
Severe rhabdomyolysis-induced acute kidney injury following concomitant use of Genvoya® (EVG/COBI/FTC/TAF) and simvastatin; a case report.
Topics: Acute Kidney Injury; Anti-HIV Agents; Cobicistat; Drug Combinations; Drug Interactions; Dyslipidemias; Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Emtricitabine; Hepatitis A; Hepatitis C; HIV Infections; Humans; Hypolipidemic Agents; Liver Function Tests; Male; Middle Aged; Quinolones; Renal Dialysis; Rhabdomyolysis; Simvastatin; Tenofovir; Treatment Outcome | 2019 |
A pilot study on the association between
Topics: Adult; Dyslipidemias; Female; Humans; Incidence; Liver-Specific Organic Anion Transporter 1; Lovastatin; Malaysia; Male; Middle Aged; Muscular Diseases; Pilot Projects; Polymorphism, Genetic; Prospective Studies; Risk Factors; Simvastatin | 2019 |
Factors associated with statin selection among privately insured commercial and Medicare patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Comorbidity; Drug Interactions; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Insurance, Health; Male; Medicare; Middle Aged; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Sex Factors; Simvastatin; Sulfonamides; United States; Young Adult | 2013 |
Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Comorbidity; Coronary Disease; Diabetes Mellitus; Drug Utilization; Drug Utilization Review; Dyslipidemias; Female; Germany; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prospective Studies; Registries; Risk Assessment; Risk Factors; Simvastatin; Time Factors; Treatment Outcome; Young Adult | 2013 |
Comparison of therapeutic lipid target achievements among high-risk patients in Oman.
Topics: Aged; Apolipoproteins; Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Oman; Practice Guidelines as Topic; Retrospective Studies; Simvastatin; Treatment Outcome | 2014 |
Risk of incident diabetes among patients treated with statins: population based study.
Topics: Aged; Atorvastatin; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Odds Ratio; Ontario; Population Surveillance; Pravastatin; Proportional Hazards Models; Pyrimidines; Pyrroles; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome | 2013 |
Severe rhabdomyolysis associated with concurrent use of simvastatin and sirolimus after cisplatin-based chemotherapy in a kidney transplant recipient.
Topics: Acute Kidney Injury; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Interactions; Dyslipidemias; Fatal Outcome; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Kidney Transplantation; Lung Neoplasms; Middle Aged; Renal Dialysis; Rhabdomyolysis; Risk Factors; Severity of Illness Index; Simvastatin; Sirolimus; Time Factors; Treatment Outcome | 2014 |
Prevalence and types of persistent dyslipidemia in patients treated with statins.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Croatia; Cross-Sectional Studies; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prevalence; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Triglycerides | 2013 |
Influence of PPARA, RXRA, NR1I2 and NR1I3 gene polymorphisms on the lipid-lowering efficacy and safety of statin therapy.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Anticholesteremic Agents; Atorvastatin; Constitutive Androstane Receptor; Dyslipidemias; Female; Genotype; Heptanoic Acids; Humans; Lipids; Male; Middle Aged; Polymerase Chain Reaction; Polymorphism, Genetic; PPAR alpha; Pregnane X Receptor; Pyrroles; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Retinoid X Receptor alpha; Risk Factors; Simvastatin; Treatment Outcome | 2013 |
Serum levels of cytokines and chemokines associated with cardiovascular disease in Brazilian patients treated with statins for dyslipidemia.
Topics: Adult; Aged; Atherosclerosis; Brazil; Cardiovascular Diseases; Chemokine CCL2; Chemokine CXCL9; Chemokines; Cytokines; Dyslipidemias; Female; Gene Expression Regulation; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome; Young Adult | 2014 |
Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Azetidines; Biomarkers; Cholesterol, LDL; Databases, Factual; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Logistic Models; Male; Managed Care Programs; Middle Aged; Multivariate Analysis; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; United States | 2013 |
Simvastatin treatment upregulates intestinal lipid secretion pathways in a rodent model of the metabolic syndrome.
Topics: Animals; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol; Disease Models, Animal; Dyslipidemias; Food Deprivation; Gene Expression Regulation; Hydrolysis; Intestines; Lipids; Lipoprotein Lipase; Male; Metabolic Syndrome; Postprandial Period; Rats; Simvastatin; Triglycerides; Up-Regulation | 2014 |
Red cabbage (Brassica oleracea L.) mediates redox-sensitive amelioration of dyslipidemia and hepatic injury induced by exogenous cholesterol administration.
Topics: Animals; Brassica; Cell Proliferation; Cell Survival; Cholesterol, Dietary; Cytoprotection; Dose-Response Relationship, Drug; Dyslipidemias; Free Radical Scavengers; Hep G2 Cells; Hepatocytes; Humans; Liver Diseases; Male; Phytotherapy; Plant Extracts; Rats; Rats, Wistar; Simvastatin | 2014 |
Comparison of Cost-Effectiveness, Safety, and Efficacy of Rosuvastatin Versus Atorvastatin, Pravastatin, and Simvastatin in Dyslipidemic Diabetic Patients With or Without Metabolic Syndrome.
Topics: Adult; Atorvastatin; Cost-Benefit Analysis; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Lipids; Male; Metabolic Syndrome; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin; Socioeconomic Factors | 2014 |
Simvastatin down-regulates the production of interleukin-8 by neutrophil leukocytes from dyslipidemic patients.
Topics: Adult; Aged; Anti-Inflammatory Agents; Biomarkers; Case-Control Studies; Down-Regulation; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation Mediators; Interleukin-8; Male; Middle Aged; Neutrophils; Simvastatin; Time Factors; Treatment Outcome | 2014 |
[Rhabdomyolysis and severe hepatotoxicity due to a drug-drug interaction between ritonavir and simvastatin. Could we use the most cost-effective statin in all human immunodeficiency virus-infected patients?].
Topics: Antiretroviral Therapy, Highly Active; Atorvastatin; Chemical and Drug Induced Liver Injury; Comorbidity; Contraindications; Cost-Benefit Analysis; Cytochrome P-450 CYP3A Inhibitors; Drug Substitution; Drug Synergism; Dyslipidemias; Female; HIV Infections; HIV Protease Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Tubular Necrosis, Acute; Middle Aged; Rhabdomyolysis; Ritonavir; Simvastatin | 2014 |
Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Comorbidity; Computer Simulation; Cost Savings; Cost-Benefit Analysis; Diabetes Mellitus; Drug Costs; Drug Substitution; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Life Style; Lipoproteins, LDL; Medicare; Models, Cardiovascular; Nuclear Magnetic Resonance, Biomolecular; Pyrroles; Quality-Adjusted Life Years; Risk; Risk Reduction Behavior; Simvastatin; Treatment Outcome; United States | 2014 |
Simvastatin prescribing patterns before and after FDA dosing restrictions: a retrospective analysis of a large healthcare claims database.
Topics: Amlodipine; Calcium Channel Blockers; Comorbidity; Drug Interactions; Drug Labeling; Drug Prescriptions; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Insurance, Health; Male; Middle Aged; Muscular Diseases; Off-Label Use; Pharmacovigilance; Practice Patterns, Physicians'; Retrospective Studies; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2015 |
Assessment of simvastatin niosomes for pediatric transdermal drug delivery.
Topics: Administration, Cutaneous; Administration, Oral; Animals; Biological Availability; Drug Delivery Systems; Dyslipidemias; Gels; Hypolipidemic Agents; Lipoproteins, HDL; Liposomes; Rats; Simvastatin; Suspensions | 2016 |
Persistent lipid abnormalities in statin-treated patients: Portuguese diabetic subpopulation of the Dyslipidaemia International Study (DYSIS).
Topics: Aged; Biomarkers; Cholesterol, LDL; Cross-Sectional Studies; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Portugal; Practice Patterns, Physicians'; Prevalence; Primary Health Care; Secondary Care; Simvastatin; Time Factors; Treatment Outcome | 2015 |
[Neurological disturbances in patient who ingested high doses of simvastatin].
Topics: Atherosclerosis; Cognition Disorders; Drug Overdose; Dyslipidemias; Electromagnetic Fields; Humans; Male; Memory Disorders; Middle Aged; Occupational Diseases; Simvastatin; Sleep Wake Disorders | 2014 |
Availability and utilization of cardiovascular fixed-dose combination drugs in the United States.
Topics: Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Comorbidity; Diabetes Mellitus; Drug Combinations; Dyslipidemias; Humans; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Lisinopril; Metformin; Practice Patterns, Physicians'; Simvastatin; United States; United States Food and Drug Administration | 2015 |
SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Topics: Aged; Atorvastatin; Czech Republic; Diabetes Mellitus; Dose-Response Relationship, Drug; Dyslipidemias; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Models, Genetic; Muscular Diseases; Myalgia; Obesity; Organic Anion Transporters; Polymorphism, Single Nucleotide; Simvastatin; Smoking | 2015 |
Influence of Retirement on Adherence to Statins in the Insurance Medicine All-Sweden Total Population Data Base.
Topics: Adult; Databases, Factual; Drug Prescriptions; Dyslipidemias; Educational Status; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Income; Male; Medication Adherence; Middle Aged; Primary Prevention; Prospective Studies; Retirement; Secondary Prevention; Simvastatin; Sweden | 2015 |
Comparison of the effects of hypolipidemic treatment on monocyte proinflammatory cytokine release in men and women with type 2 diabetes and atherogenic dyslipidemia.
Topics: Atherosclerosis; C-Reactive Protein; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Monocytes; Sex Factors; Simvastatin | 2015 |
Icariin Attenuates High-cholesterol Diet Induced Atherosclerosis in Rats by Inhibition of Inflammatory Response and p38 MAPK Signaling Pathway.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Diet, High-Fat; Disease Models, Animal; Down-Regulation; Drugs, Chinese Herbal; Dyslipidemias; Flavonoids; Inflammation; Interleukin-6; Lipids; Male; Malondialdehyde; MAP Kinase Signaling System; Oxidative Stress; p38 Mitogen-Activated Protein Kinases; Rats; Rats, Wistar; RNA, Messenger; Simvastatin; Superoxide Dismutase; Triglycerides; Tumor Necrosis Factor-alpha | 2016 |
A population-based analysis of the risk of drug interaction between clarithromycin and statins for hospitalisation or death.
Topics: Adult; Aged; Atorvastatin; Cardiovascular Diseases; Clarithromycin; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Dyslipidemias; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Retrospective Studies; Risk; Rosuvastatin Calcium; Simvastatin | 2015 |
The effect of hypolipidemic treatment on monocyte cytokine release in different age groups of patients with type 2 diabetes and atherogenic dyslipidemia.
Topics: Adult; Age Factors; Aged; Atherosclerosis; Cytokines; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Middle Aged; Monocytes; Retrospective Studies; Simvastatin; Treatment Outcome; Young Adult | 2016 |
RP1-13D10.2 Is a Novel Modulator of Statin-Induced Changes in Cholesterol.
Topics: Adult; Aged; Apolipoprotein B-100; Biomarkers; Cholesterol, LDL; Clinical Trials as Topic; Dyslipidemias; Female; Hep G2 Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Male; Middle Aged; Polymorphism, Single Nucleotide; Receptors, LDL; RNA, Long Noncoding; RNA, Messenger; Simvastatin; Time Factors; Transcription, Genetic; Transfection; Up-Regulation | 2016 |
The effect of the intensity of lipid-lowering medications on the LDL cholesterol treatment goals of Asian patients with dyslipidaemia in primary care.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Asian People; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Cross-Sectional Studies; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Primary Health Care; Risk Factors; Rosuvastatin Calcium; Simvastatin | 2016 |
[Public sector participation in the supply of dyslipidemia medication in a population-based study].
Topics: Adult; Aged; Bezafibrate; Brazil; Cardiovascular Diseases; Cross-Sectional Studies; Dyslipidemias; Female; Humans; Hypolipidemic Agents; Interviews as Topic; Male; Middle Aged; Prevalence; Public Sector; Simvastatin | 2016 |
Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Blood Pressure; Cardiovascular Diseases; Cause of Death; Cholesterol, LDL; Dyslipidemias; Female; Humans; Hypertension; Male; Middle Aged; Mortality; Myocardial Infarction; Proportional Hazards Models; Randomized Controlled Trials as Topic; Secondary Prevention; Simvastatin; Stroke | 2017 |
Cost-effectiveness of the polypill versus risk assessment for prevention of cardiovascular disease.
Topics: Administration, Oral; Adult; Aged; Amlodipine; Antihypertensive Agents; Cardiovascular Diseases; Computer Simulation; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Dyslipidemias; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Losartan; Male; Middle Aged; Models, Economic; Primary Prevention; Quality-Adjusted Life Years; Risk Assessment; Risk Factors; Simvastatin; Tablets; Time Factors; Treatment Outcome | 2017 |
Treatment of obese asthma in a mouse model by simvastatin is associated with improving dyslipidemia and decreasing leptin level.
Topics: Animals; Asthma; Blood Glucose; Body Weight; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Dyslipidemias; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leptin; Leukocyte Count; Lipids; Lung; Mice; Mice, Inbred C57BL; Obesity; Simvastatin | 2017 |
Simvastatin-associated dermatomyositis.
Topics: Aged; Dermatomyositis; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2017 |
Safety and efficacy of simvastatin for the treatment of dyslipidemia in human immunodeficiency virus-infected patients receiving efavirenz-based highly active antiretroviral therapy.
Topics: Aged; Aged, 80 and over; Alkynes; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; Benzoxazines; CD4 Lymphocyte Count; Cohort Studies; Cyclopropanes; Dyslipidemias; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Retrospective Studies; Simvastatin; Viral Load | 2008 |
A drug, a concept, and a clinical trial on trial.
Topics: Azetidines; Clinical Trials as Topic; Dyslipidemias; Evidence-Based Medicine; Ezetimibe; Humans; Research Design; Simvastatin; United States; United States Food and Drug Administration | 2008 |
Antidiabetic effects of 11beta-HSD1 inhibition in a mouse model of combined diabetes, dyslipidaemia and atherosclerosis.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Adipose Tissue; Animals; Atherosclerosis; Blood Glucose; Body Composition; Body Weight; Cholesterol; Diabetes Mellitus, Type 2; Disease Models, Animal; Dyslipidemias; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metabolic Syndrome; Mice; Mice, Knockout; Rosiglitazone; Simvastatin; Thiazolidinediones; Triglycerides | 2009 |
Rhein improves renal lesion and ameliorates dyslipidemia in db/db mice with diabetic nephropathy.
Topics: Albuminuria; Animals; Anthraquinones; Anticholesteremic Agents; Cholesterol; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Drugs, Chinese Herbal; Dyslipidemias; Extracellular Matrix; Fibronectins; Kidney; Mice; Mice, Inbred C57BL; Mice, Knockout; Phytotherapy; Rheum; Rhizome; Simvastatin; Transforming Growth Factor beta1 | 2010 |
The efficacy and safety of ezetimibe and low-dose simvastatin as a primary treatment for dyslipidemia in renal transplant recipients.
Topics: Adult; Azetidines; C-Reactive Protein; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Transplantation; Male; Middle Aged; Prospective Studies; Simvastatin | 2009 |
Atherosclerosis regression study in rabbits upon olive pomace polar lipid extract administration.
Topics: Analysis of Variance; Animals; Atherosclerosis; Cholesterol; Diet, Atherogenic; Dietary Supplements; Disease Models, Animal; Dyslipidemias; Male; Olea; Olive Oil; Plant Oils; Platelet Aggregation; Rabbits; Regression Analysis; Simvastatin | 2010 |
Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.
Topics: Aged; Atorvastatin; Clinical Trials, Phase III as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
[Correction of antioxidative state during statin therapy of coronary heart disease with dyslipidemia].
Topics: Antioxidants; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Male; Middle Aged; Oxidative Stress; Picolines; Simvastatin; Treatment Outcome | 2009 |
Cost-effectiveness of rosuvastatin versus ezetimibe/simvastatin in managing dyslipidemic patients in Mexico.
Topics: Aged; Azetidines; Cost-Benefit Analysis; Dyslipidemias; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mexico; Middle Aged; Pyrimidines; Retrospective Studies; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2010 |
"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.
Topics: Biomarkers; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Evidence-Based Medicine; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; Triglycerides | 2010 |
Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Allylamine; Anticholesteremic Agents; Azetidines; Biomarkers; Cholesterol, LDL; Colesevelam Hydrochloride; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fatty Acids, Omega-3; Female; Humans; Inflammation; Life Style; Male; Middle Aged; Niacin; Regression Analysis; Retrospective Studies; Risk Factors; Simvastatin; Statistics as Topic; Vitamin B Complex | 2010 |
[Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].
Topics: Aged; Atherosclerosis; Cardiovascular Diseases; Diabetes Complications; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Multicenter Studies as Topic; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Simvastatin | 2010 |
Effect of ezetimibe-simvastatine over endothelial dysfunction in dyslipidemic patients: assessment by 13N-ammonia positron emission tomography.
Topics: Adenosine; Adolescent; Adult; Aged; Ammonia; Anticholesteremic Agents; Azetidines; Case-Control Studies; Dyslipidemias; Endothelium, Vascular; Ezetimibe; Female; Humans; Male; Middle Aged; Myocardium; Nitrogen Isotopes; Positron-Emission Tomography; Prospective Studies; Risk Factors; Simvastatin | 2010 |
The effect of simvastatin on lymphocyte secretory function in patients with impaired fasting glucose.
Topics: Blood Glucose; Dyslipidemias; Fasting; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Interferon-gamma; Interleukin-2; Lipids; Lymphocytes; Male; Middle Aged; Simvastatin; Tumor Necrosis Factor-alpha | 2010 |
Metabolomic anatomy of an animal model revealing homeostatic imbalances in dyslipidaemia.
Topics: Animals; Disease Models, Animal; Dyslipidemias; Gene Expression Regulation; Homeostasis; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Metabolism; Lipids; Liver; Male; Metabolomics; Oxidative Stress; Rabbits; Simvastatin; Xanthine Oxidase | 2011 |
Adherence to single-pill combination versus multiple-pill combination lipid-modifying therapy among patients with mixed dyslipidemia in a managed care population.
Topics: Aged; Anticholesteremic Agents; Azetidines; Databases, Factual; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Lovastatin; Male; Middle Aged; Niacin; Patient Compliance; Retrospective Studies; Simvastatin; Time Factors | 2011 |
Validation of human ApoB and ApoAI immunoturbidity assays for non-human primate dyslipidemia and atherosclerosis research.
Topics: Animals; Apolipoprotein A-I; Apolipoproteins B; Atherosclerosis; Biomarkers; Calibration; Disease Models, Animal; Dyslipidemias; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Haplorhini; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoassay; Mass Spectrometry; Nephelometry and Turbidimetry; Predictive Value of Tests; Reproducibility of Results; Simvastatin | 2011 |
Persistent lipid abnormalities in patients treated with statins: Portuguese results of the Dyslipidemia International Study (DYSIS).
Topics: Azetidines; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Portugal; Simvastatin; Triglycerides | 2011 |
Cost-effectiveness of extended-release niacin/laropiprant added to a stable simvastatin dose in secondary prevention patients not at cholesterol goal in Germany.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cost-Benefit Analysis; Drug Therapy, Combination; Dyslipidemias; Female; Germany; Health Care Costs; Humans; Hypolipidemic Agents; Indoles; Life Expectancy; Male; Middle Aged; Models, Economic; Niacin; Risk Assessment; Secondary Prevention; Simvastatin | 2012 |
Niacin extended-release therapy in phase III clinical trials is associated with relatively low rates of drug discontinuation due to flushing and treatment-related adverse events: a pooled analysis.
Topics: Clinical Trials, Phase III as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Flushing; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Medication Adherence; Middle Aged; Niacin; Simvastatin | 2011 |
Weighing the benefits of high-dose simvastatin against the risk of myopathy.
Topics: Anticholesteremic Agents; Creatine Kinase; Drug Approval; Drug Interactions; Drug Labeling; Dyslipidemias; Humans; Muscular Diseases; Risk; Simvastatin; United States; United States Food and Drug Administration | 2011 |
Low-density lipoprotein cholesterol goal attainment among Malaysian dyslipidemic patients.
Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Disease; Dyslipidemias; Female; Fluorobenzenes; Heptanoic Acids; Humans; Logistic Models; Malaysia; Male; Pravastatin; Pyrimidines; Pyrroles; Retrospective Studies; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Therapy and clinical trials: aggressive statin therapy versus combined and emerging approaches.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Clinical Trials as Topic; Dyslipidemias; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2011 |
Acrolein-induced dyslipidemia and acute-phase response are independent of HMG-CoA reductase.
Topics: Acrolein; Acute-Phase Reaction; Animals; Apolipoproteins E; Cholesterol; Dyslipidemias; Gene Expression Regulation; Hydroxymethylglutaryl CoA Reductases; Liver; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Serum Amyloid A Protein; Simvastatin; Toxicity Tests, Acute; Toxicity Tests, Chronic; Triglycerides; Xenobiotics | 2011 |
Naringin ameliorates atherogenic dyslipidemia but not hyperglycemia in rats with type 1 diabetes.
Topics: Animals; Atherosclerosis; Blood Glucose; Cholesterol; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Dyslipidemias; Flavanones; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperglycemia; Hypoglycemic Agents; Insulin; Male; Rats; Rats, Wistar; Simvastatin; Streptozocin | 2012 |
Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia.
Topics: Animals; Cricetinae; Disease Models, Animal; Dogs; Dyslipidemias; Fatty Acids; Humans; Lipids; Mice; Primates; Simvastatin; Triglycerides | 2012 |
Lipid-lowering drugs as primary prevention in general practice: do patients reach guideline goals and continue treatment? ADDITION Denmark.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Cardiovascular Diseases; Cross-Sectional Studies; Dyslipidemias; Female; Follow-Up Studies; General Practice; Goals; Guideline Adherence; Humans; Hypolipidemic Agents; Male; Medication Adherence; Middle Aged; Outcome Assessment, Health Care; Primary Prevention; Risk Factors; Simvastatin | 2011 |
Statin therapy, myopathy and exercise--a case report.
Topics: Adult; Dyslipidemias; Exercise; Humans; Hypolipidemic Agents; Male; Muscular Diseases; Physical Exertion; Simvastatin | 2012 |
Déjà vu all over again.
Topics: Arterial Occlusive Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Female; Humans; Male; Simvastatin | 2012 |
Persistent use of against-label statin-fibrate combinations from 2003-2009 despite United States Food and Drug Administration dose restrictions.
Topics: Cohort Studies; Dose-Response Relationship, Drug; Drug Labeling; Drug Therapy, Combination; Dyslipidemias; Female; Fibric Acids; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Off-Label Use; Practice Patterns, Physicians'; Retrospective Studies; Simvastatin; United States; United States Food and Drug Administration | 2012 |
Statin related memory dysfunction in a Nigerian woman: a case report.
Topics: Activities of Daily Living; Adult; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Memory Disorders; Nigeria; Simvastatin | 2012 |
Letter by Kuller and Mackey regarding article, "Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection study".
Topics: Arterial Occlusive Diseases; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dyslipidemias; Female; Humans; Male; Simvastatin | 2012 |
Possible gene-gender interaction between the SLCO1B1 polymorphism and statin treatment efficacy.
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias; Female; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Organic Anion Transporters; Pilot Projects; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Polymorphism, Single Nucleotide; Pyrroles; Retrospective Studies; Sex Factors; Simvastatin; Triglycerides | 2012 |
Lipid-lowering pharmacotherapy in Central and Eastern European countries in cardiovascular prevention: self-reported prescription patterns of primary care physicians.
Topics: Adult; Atorvastatin; Cardiovascular Diseases; Cross-Sectional Studies; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Europe; Female; Health Care Surveys; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Physicians, Primary Care; Practice Guidelines as Topic; Practice Patterns, Physicians'; Pyrroles; Risk; Secondary Care; Self Report; Simvastatin | 2013 |
Targeting healthcare disparities: an integrated model to improve treatment rates of dyslipidemia in African American patients.
Topics: Alcohol Drinking; Ambulatory Care; Atherosclerosis; Black People; Cholesterol, LDL; Clinical Protocols; Coronary Artery Disease; Curriculum; Diabetes Mellitus; Diet; Dyslipidemias; Female; Georgia; Humans; Hypolipidemic Agents; Internal Medicine; Internship and Residency; Male; Middle Aged; Patient Education as Topic; Risk Factors; Simvastatin; Smoking | 2005 |
Time as a variable with niacin extended-release/lovastatin vs. atorvastatin and simvastatin.
Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Niacin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2005 |
Differential associations of statin and fibrate treatment with carotid arterial remodeling.
Topics: Adult; Atorvastatin; Bezafibrate; Body Mass Index; Carotid Arteries; Cholesterol, HDL; Clofibric Acid; Cohort Studies; Dyslipidemias; Fatty Acids, Monounsaturated; Female; Fenofibrate; Fibric Acids; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Multivariate Analysis; Pravastatin; Pyridines; Pyrroles; Risk Factors; Simvastatin; Treatment Outcome; Tunica Intima; Tunica Media; Ultrasonography | 2005 |
[Drug combinations: statins and niacin].
Topics: Age Distribution; Atherosclerosis; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Interactions; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Niacin; Pyrroles; Sex Factors; Simvastatin | 2005 |
Ezetimibe: effective and safe treatment for dyslipidaemia associated with nonalcoholic fatty liver disease. Response to: Toth PP, Davidson MH: simvastatin and ezetimibe: combination therapy for the management of dyslipidaemia. Expert Opin. Pharmacother. (
Topics: Anticholesteremic Agents; Azetidines; Drug Combinations; Dyslipidemias; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Fatty Liver; Humans; Insulin Resistance; Simvastatin | 2006 |
Lipids: new guidelines, intensive treatment, and future directions.
Topics: Comorbidity; Coronary Disease; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Particle Size; Practice Guidelines as Topic; Simvastatin | 2006 |
[Efficacy of simvastatin in elderly patients with type 2 diabetes].
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Simvastatin; Treatment Outcome | 2006 |
Safety of lovastatin/extended release niacin compared with lovastatin alone, atorvastatin alone, pravastatin alone, and simvastatin alone (from the United States Food and Drug Administration adverse event reporting system).
Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Prescriptions; Drug Therapy, Combination; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver Diseases; Lovastatin; Niacin; Pravastatin; Prevalence; Pyrroles; Retrospective Studies; Rhabdomyolysis; Risk Factors; Simvastatin; United States; United States Food and Drug Administration | 2007 |
A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets.
Topics: Atorvastatin; Canada; Cholesterol, LDL; Cost-Benefit Analysis; Drug Costs; Dyslipidemias; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Models, Economic; Pyrroles; Simvastatin | 2007 |
Prolonged statin-associated reduction in neutrophil reactive oxygen species and angiotensin II type 1 receptor expression: 1-year follow-up.
Topics: Anticholesteremic Agents; Coronary Artery Disease; Dyslipidemias; Female; Follow-Up Studies; Gene Expression; Humans; Longitudinal Studies; Male; Middle Aged; Neutrophils; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Simvastatin; Up-Regulation | 2008 |
Simcor: a niacin/simvastatin combination.
Topics: Cholesterol, HDL; Cholesterol, LDL; Costs and Cost Analysis; Drug Combinations; Drug Interactions; Dyslipidemias; Humans; Niacin; Simvastatin; Triglycerides | 2008 |
Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.
Topics: Diabetes Mellitus; Drug Therapy, Combination; Dyslipidemias; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins; Simvastatin; Treatment Outcome | 2008 |